BRCA1 and ovarian serous adenocarcinoma: They inferred that high grade serous ovarian cancer with mutations in BRCA1/2 may be more sensitive to immune checkpoint inhibitors PD-1 and PD-L1 in comparison with tumors proficient in HR repair [29].